Pelthos Therapeutics Inc.
PTHS$25.63 +2.96 (13.06%)
Company News
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
Ligand Pharmaceuticals announced 2026 full year revenue guidance of $245-$285 million, representing a 15% core revenue growth, with strong expectations for royalty revenue from key pharmaceutical products.
